title: The prognostic impact of EGFR, ErbB2 and MET gene amplification in human gastric carcinomas as measured by quantitative Real-Time PCR.
abstract: OBJECTIVE
  Identification of critical genes which play pivotal roles in controlling tumor growth and survival will establish the basis for developing therapeutic targets. In this study, we focused on frequencies of EGFR, ErbB2 and MET gene amplification in gastric cancer patients to develop personalized medicine to improve the treatment.
  
  
  METHODS
  EGFR, ErbB2 and MET gene amplification, and mRNA expression were analyzed by the quantitative Real-Time PCR in paraffin-embedded samples from 115 patients with gastric cancer.
  
  
  RESULTS
  EGFR, ErbB2 and MET genes were amplified in 11.3 % (13/115), 6.1 % (7/115) and 19.1 % (22/115) of cancerous specimens, respectively. The correlation coefficient test clearly indicated that gene amplification in these three genes was positively correlated with mRNA transcription (EGFR: R = 0.631, p = 0.009; ErbB2: R = 0.652, p = 0.023; MET: R = 0.715, p < 0.001). EGFR and MET gene amplification was significantly associated with Ki-67 MI (p = 0.022 and p = 0.015). MET amplification was also significantly associated with age of ≥60 years (p = 0.021) and tumor size of ≥5 cm (p = 0.032). MET amplification, but not EGFR and ErbB2, was a significant prognostic factor in poor survival among patients with gastric cancer.
  
  
  CONCLUSIONS
  EGFR, ErbB2 and MET genes are frequently amplified in gastric carcinoma. EGFR, ErbB2 and MET gene amplification is positively correlated with mRNA transcription. MET gene amplification correlates with a poor prognosis and poor survival in gastric carcinomas.
authors.affiliation: Inflammatory Diseases of Upper Gastrointestinal Tract Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
authors.forename: Ghasem
authors.initials: G
authors.lastname: Janbabai
authors.affiliation: Inflammatory Diseases of Upper Gastrointestinal Tract Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
authors.forename: Ziaeddin
authors.initials: Z
authors.lastname: Oladi
authors.affiliation: Inflammatory Diseases of Upper Gastrointestinal Tract Research Center, Mazandaran University of Medical Sciences, Sari, Iran. tourajf@yahoo.com.|Faculty of Advanced Medical Science Technologies, Golestan University of Medical Sciences, Gorgan, Iran. tourajf@yahoo.com.|Cancer Research Center, Mazandaran University of Medical Sciences, P.O. Box 4817773913, Sari, Iran. tourajf@yahoo.com.
authors.forename: Touraj
authors.initials: T
authors.lastname: Farazmandfar
authors.affiliation: Inflammatory Diseases of Upper Gastrointestinal Tract Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
authors.forename: Tarang
authors.initials: T
authors.lastname: Taghvaei
authors.affiliation: Department of Pathology, Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Iran.
authors.forename: Farshad
authors.initials: F
authors.lastname: Naghshvar
mesh_terms: D056915:DNA Copy Number Variations / Q000235:genetics; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D005784:Gene Amplification; D018628:Gene Dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D019859:Proto-Oncogene Proteins c-met / Q000235:genetics*; D012333:RNA, Messenger / Q000096:biosynthesis; D060888:Real-Time Polymerase Chain Reaction; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*; D013274:Stomach Neoplasms / Q000235:genetics*
chemical_list: D066246:ErbB Receptors; D019859:Proto-Oncogene Proteins c-met; D012333:RNA, Messenger; D018719:Erb-b2 Receptor Tyrosine Kinases; C512478:EGFR protein, human; C508053:ERBB2 protein, human; C491743:MET protein, human
keywords: EGFR; ErbB2; Gastric cancer; Gene amplification; MET
references.citation: Mod Pathol. 2004 May;17(5):579-87
references.pmid: 15073595
references.citation: Histopathology. 2008 May;52(6):738-46
references.pmid: 18397279
references.citation: Curr Opin Cell Biol. 2009 Apr;21(2):304-10
references.pmid: 19328671
references.citation: Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37
references.pmid: 11252954
references.citation: Clin Cancer Res. 2003 Nov 1;9(14):5346-57
references.pmid: 14614020
references.citation: Int J Cancer. 1993 Aug 19;55(1):72-5
references.pmid: 8344755
references.citation: Nature. 2010 Feb 18;463(7283):899-905
references.pmid: 20164920
references.citation: Oncol Rep. 2011 Jun;25(6):1517-24
references.pmid: 21424128
references.citation: Mol Cytogenet. 2011 Jun 20;4(1):14
references.pmid: 21689422
references.citation: Clin Cancer Res. 2007 May 15;13(10):3051-7
references.pmid: 17505008
references.citation: Cancer Res Treat. 2004 Aug;36(4):240-5
references.pmid: 20368841
references.citation: Cancer. 1999 May 1;85(9):1894-902
references.pmid: 10223227
references.citation: Lancet. 2010 Aug 28;376(9742):687-97
references.pmid: 20728210
references.citation: Oncologist. 2002;7 Suppl 4:31-9
references.pmid: 12202786
references.citation: Oncogene. 2000 Oct 12;19(43):4947-53
references.pmid: 11042681
references.citation: Br J Cancer. 2009 Mar 10;100(5):732-8
references.pmid: 19259093
references.citation: J Clin Oncol. 2011 Dec 20;29(36):4789-95
references.pmid: 22042954
references.citation: Ann Surg Oncol. 2003 Apr;10(3):234-41
references.pmid: 12679307
references.citation: Br J Cancer. 2012 Jul 10;107(2):325-33
references.pmid: 22644302
references.citation: J Cell Physiol. 2004 Sep;200(3):343-50
references.pmid: 15254961
references.citation: Br J Cancer. 2012 Feb 14;106(4):727-32
references.pmid: 22240789
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: N Engl J Med. 2010 Mar 4;362(9):858-9
references.pmid: 20200397
references.citation: Ann Oncol. 2008 Nov;19(11):1882-7
references.pmid: 18669868
references.citation: BMC Cancer. 2012 Nov 15;12:524
references.pmid: 23153332
references.citation: Ann Surg Oncol. 2008 Jan;15(1):69-79
references.pmid: 17896140
references.citation: Trends Mol Med. 2010 Jan;16(1):37-45
references.pmid: 20031486
references.citation: J Natl Cancer Inst. 1986 Nov;77(5):1047-52
references.pmid: 3464796
references.citation: J Clin Oncol. 2002 Feb 1;20(3):719-26
references.pmid: 11821453
references.citation: Int J Oncol. 2013 Apr;42(4):1151-8
references.pmid: 23426935
references.citation: Virchows Arch. 1997 Dec;431(6):383-9
references.pmid: 9428926
references.citation: Oncotarget. 2013 Jan;4(1):9-17
references.pmid: 23327903
references.citation: Oncology. 2008;74(1-2):76-83
references.pmid: 18544998
references.citation: APMIS. 2000 Mar;108(3):195-200
references.pmid: 10752688
references.citation: Cancer Genet Cytogenet. 1995 Jul 15;82(2):140-5
references.pmid: 7664243
references.citation: Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25
references.pmid: 14685170
references.citation: Diagn Pathol. 2013 Feb 04;8:16
references.pmid: 23379953
references.citation: Trends Genet. 2006 Aug;22(8):447-55
references.pmid: 16787682
references.citation: Cancer. 1995 Mar 15;75(6 Suppl):1410-7
references.pmid: 7889467
references.citation: World J Surg. 2007 Jul;31(7):1458-68
references.pmid: 17516110
references.citation: J Clin Oncol. 2006 Nov 1;24(31):4991-7
references.pmid: 17075117
references.citation: J Med Genet. 2001 Aug;38(8):E26
references.pmid: 11483642